Deferasirox Impurity 15

Identification, characterization and quantification of a new impurity in deferasirox active pharmaceutical ingredient by LC–ESI–QT/MS/MS
Saji Thomas a,∗, Subhash Chandra Joshi a, Dharam Vir b, Ashutosh Agarwal b, Raghavendra Desai Raoc, I. Sridhar c, Cijo M. Xavier c, Chandra S. Mathela
Journal of Pharmaceutical and Biomedical Analysis 63 (2012) 112–119
 
Determination and Characterization of Two Degradant Impurities in Bendamustine Hydrochloride Drug Product
Wenhua Chen, Limin Zou, Fei Zhang, Xiangyang Xu, Liandi Zhang, Mingyi Liao, Xiaoqiang Li, Li Ding
Journal of Chromatographic Science, Volume 53, Issue 10, November/December 2015, Pages 1673–1679
 
Metal complexation of deferasirox derivatives: A solid state and equilibrium study
ImreNagyaGergőFerenczikaLindaBíróaEtelkaFarkasaAttilaCs. BényeibPéterBuglyóa
Polyhedron Volume 190, 1 November 2020, 114780

Deferasirox Impurity 15 is chemically 4-(3-(5-((3-(1-(4-Carboxyphenyl)-3-(2-hydroxyphenyl)-1H-1,2,4-triazol-5-yl)-4-hydroxyphenyl)sulfinyl)-2-hydroxyphenyl)-5-(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoic acid. Deferasirox Impurity 15 is supplied with detailed characterization data compliant with regulatory guideline. Deferasirox Impurity 15 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Deferasirox.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.